Lili Yang, Ph.D.
Dr. Yang received her Ph.D. degree in Biology from the California Institute of Technology (Caltech) in 2004, studying with Dr. David Baltimore. Post graduation, she stayed at Caltech and led a multi-institutional Engineering Immunity Program from 2004 to 2012, developing gene- and cell-based immunotherapies for cancer and HIV/AIDS. She joined the faculty of University of California, Los Angeles (UCLA) in 2013 and is currently an Associate Professor of Microbiology, Immunology and Molecular Genetics. Her laboratory at UCLA studies tumor immunology and cancer immunotherapy, with a special focus on stem cell-based and gene-engineered immunotherapy for cancer. So far her research has resulted in 35 peer-reviewed publications (on Nature, Nature Biotechnology, Cell Stem Cell, PNAS, J Exp Med, J Clin Invest, Blood, etc.), 15 patents, 2 clinical trials, and 2 biotech startups. For the recognition of her scientific achievements, Dr. Yang has received multiple prestigious awards, including the TR35 (Innovators Under 35) Award from the MIT Technology Review Magazine, the Forbeck Scholar Award, the Director’s New Innovator Award from the National Institute of Health (NIH), the Translational Research Project Award from the California Institute for Regenerative Medicine (CIRM), the Young Investigator Award from the American Association of Immunologists (AAI), and the Outstanding New Investigator Award from the American Society of Gene & Cell Therapy (ASGCT).”